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Background
The E3 ubiquitin ligase cbl-b has been identified as a
key intracellular checkpoint limiting T and NK cell acti-
vation. Concordantly, blockade of cbl-b function by
genetic deletion strongly enhances anti-tumor immune
responses, thereby validating cbl-b as target for immu-
notherapy. We have recently shown in the B16-OVA
model that transfer of transiently cbl-b silenced murine
T cells together with DC vaccination could suppress
tumor growth. This provides a rationale to combine
administration of cbl-b silenced PBMCs with an estab-
lished DC vaccination protocol. We present here a case
study for the treatment of a patient suffering from lung
metastases originating from pancreatic cancer.
Methods
PBMCs were isolated ex vivo from the cancer patient
and transfected with cbl-b siRNA by electroporation.
DCs were pulsed with lysates of pancreatic tumor cell
lines serving as antigen source and co-administrated
with the PBMCs intranodally to the cancer patient. The
composition and phenotype of the immune compart-
ment of the patient was regularly monitored at each
treatment by flow cytometry. The phenotype and activa-
tion of DCs and cbl-b silenced PBMCs was assessed by
flow cytometry and ELISA. Tumor progression was
monitored by determination of CA19-9 blood levels and
computer tomography.
Results
Ex vivo Transfection of cancer patient PBMCs with cbl-b
si RNA resulted in strong suppression of cbl-b expression
and enhanced T cell activation. No adverse events were
observed when cbl-b silenced PBMCs (up to 1.5*10^8)
were administrated to the patient. When cbl-b silenced
PBMCs were co-administrated with activated DCs, no
worsening of DC-associated slight fever and local DTH
reactions was observed. Overall, 2 vaccination cycles (each
10 single treatments with DCs and cbl-b silenced PBMCs)
were administrated. During the treatment, massive fluc-
tuations in the PBMC immune compartments were
observed, indicating the impact on the patient`s immune
system. Tumor progression was slowed during the treat-
ment periods, resulting in disease control over a period of
more than 30 months.
Conclusions
The adoptive cell therapy protocol combining DC vaccina-
tion and ex vivo cbl-b silencing was shown to be feasible
and well tolerated. Moreover, immunologic effects and
slowed tumor growth suggest beneficial effects of the
treatment. Based on these results, a Phase I trial for adop-
tive cell therapy with larger numbers of cbl-b silenced
PBMCs was started at Wake Forest University.
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